ARCEDI Biotech, Vejle, Denmark.
Department of Clinical Medicine, Faculty of Health, Center for Fetal Diagnostics, Aarhus University, Aarhus, Denmark.
Prenat Diagn. 2023 Jun;43(7):854-864. doi: 10.1002/pd.6387. Epub 2023 May 25.
We aimed to compare cell-based NIPT (cbNIPT) to chorionic villus sampling (CVS) and to examine the test characteristics of cbNIPT in the first clinical validation study of cbNIPT compared to cell-free NIPT (cfNIPT).
Study 1: Women (N = 92) who accepted CVS were recruited for cbNIPT (53 normal and 39 abnormal). Samples were analyzed with chromosomal microarray (CMA). Study 2: Women (N = 282) who accepted cfNIPT were recruited for cbNIPT. cfNIPT was analyzed using sequencing and cbNIPT by CMA.
Study 1: cbNIPT detected all aberrations (32/32) found in CVS: trisomies 13, 18 and 21 (23/23), pathogenic copy number variations (CNVs) (6/6) and sex chromosome aberrations (3/3). cbNIPT detected 3/8 cases of mosaicism in the placenta. Study 2: cbNIPT detected all trisomies found with cfNIPT (6/6) and had no false positive (0/246). One of the three CNVs called by cbNIPT was confirmed by CVS but was undetected by cfNIPT, two were false positives. cbNIPT detected mosaicism in five samples, of which two were not detected by cfNIPT. cbNIPT failed in 7.8% compared to 2.8% in cfNIPT.
Circulating trophoblasts in the maternal circulation provide the potential of screening for aneuploidies and pathogenic CNVs covering the entire fetal genome.
我们旨在比较基于细胞的无创性产前检测(cbNIPT)与绒毛膜取样(CVS),并在首次将 cbNIPT 与游离胎儿 DNA 无创性产前检测(cfNIPT)进行比较的临床验证研究中,研究 cbNIPT 的检测特性。
研究 1:接受 CVS 的女性(N=92)被招募进行 cbNIPT(53 例正常,39 例异常)。样本用染色体微阵列(CMA)分析。研究 2:接受 cfNIPT 的女性(N=282)被招募进行 cbNIPT。cfNIPT 用测序分析,cbNIPT 用 CMA 分析。
研究 1:cbNIPT 检测到 CVS 中发现的所有异常(32/32):三体 13、18 和 21(23/23)、致病性拷贝数变异(CNVs)(6/6)和性染色体异常(3/3)。cbNIPT 检测到胎盘中的 3/8 例嵌合体。研究 2:cbNIPT 检测到 cfNIPT 发现的所有三体(6/6),且无假阳性(0/246)。cbNIPT 检出的 3 个 CNVs 中有 1 个被 CVS 证实,但 cfNIPT 未检出,2 个为假阳性。cbNIPT 在 5 个样本中检测到嵌合体,其中 2 个未被 cfNIPT 检出。cbNIPT 的失败率为 7.8%,cfNIPT 为 2.8%。
母体循环中的循环滋养细胞为筛查整个胎儿基因组的非整倍体和致病性 CNVs 提供了潜力。